HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hwang, W. J. Articles by Ting, G. Search for Related Content PubMed PubMed Citation Articles by Hwang, W. J. Articles by Ting, G.

Reproducibility of ^99mTc-TRODAT-1 SPECT Measurement of Dopamine Transporters in Parkinson’s Disease

¹ Department of Neurology, College of Medicine, National Cheng Kung University, Tainan, Taiwan
² Department of Nuclear Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan
³ Division of Radiological Technology, School of Medical Technology, Chang Gung University, Taoyuan, Taiwan
⁴ Institute of Nuclear Energy Research, Lung-Tan, Taiwan

Functional brain imaging targeting the presynaptic dopamine nerve terminal of the nigrostriatal system has been used for monitoring disease progression and evaluating therapeutic effectiveness in patients with Parkinson’s disease (PD). ^99mTc-TRODAT-1 binds with high selectivity to the dopamine transporters in the striatum and can be imaged with SPECT 4 h after injection. We studied the test and retest reproducibility of ^99mTc-TRODAT-1 SPECT measures in patients with PD to assess the reliability of ^99mTc-TRODAT-1 for longitudinal evaluation of the nigrostriatal dopaminergic function. Methods: Each of 20 patients with PD underwent 2 ^99mTc-TRODAT-1 SPECT scans at an interval of 2–3 wk. Patients were imaged 4 h after injection of 925 MBq ^99mTc-TRODAT-1. Two imaging outcome measures were evaluated: the ratio of specific-striatal-to-nonspecific uptake and the striatal asymmetry index. For both measures, the test/retest variability was calculated. Reproducibility of the 2 outcome measures was evaluated in terms of intraclass correlation coefficient (ICC) and 95% limits of agreement. Results: The mean ratio of specific-striatal-to-nonspecific uptake showed excellent test/retest reproducibility with a mean variability of 10.20%, an ICC of 0.95 (95% confidence interval = 0.88–0.98), and 95% limits of agreement, ranging from -0.19 to 0.19. The striatal asymmetry index had larger test/retest variability (60.41%), a slightly smaller ICC of 0.86 (95% confidence interval = 0.65–0.95), and a wider range of 95% limits of agreement (-16.09 to 15.19). In addition, there was a significant negative correlation between the mean ratio of specific-striatal-to-nonspecific uptake and the motor subscore of the Unified Parkinson’s Disease Rating Scale in both test and retest conditions. Conclusion: Our data indicate that the imaging outcome expressed by the mean ratio of specific-striatal-to-nonspecific uptake has an excellent test/retest reproducibility and correlates with disease severity. These findings suggest that ^99mTc-TRODAT-1 SPECT imaging is useful and feasible for measuring disease progression in PD.

Key Words: dopamine transporter • SPECT • Parkinson’s disease • ^99mTc-TRODAT-1

This article has been cited by other articles:

				W. Koch, O. Pogarell, G. Popperl, J. Hornung, C. Hamann, F.-J. Gildehaus, K. Seelos, D. Lewis, A. Favit, and K. Tatsch Extended Studies of the Striatal Uptake of 99mTc-NC100697 in Healthy Volunteers J. Nucl. Med., January 1, 2007; 48(1): 27 - 34. [Abstract] [Full Text] [PDF]

				W. Koch, C. Hamann, J. Welsch, G. Popperl, P. E. Radau, and K. Tatsch Is Iterative Reconstruction an Alternative to Filtered Backprojection in Routine Processing of Dopamine Transporter SPECT Studies? J. Nucl. Med., November 1, 2005; 46(11): 1804 - 1811. [Abstract] [Full Text] [PDF]

				W. Koch, P. E. Radau, C. Hamann, and K. Tatsch Clinical Testing of an Optimized Software Solution for an Automated, Observer-Independent Evaluation of Dopamine Transporter SPECT Studies J. Nucl. Med., July 1, 2005; 46(7): 1109 - 1118. [Abstract] [Full Text] [PDF]

				S. A. Gardiner, M. F. Morrison, P. D. Mozley, L. H. Mozley, C. Brensinger, W. Bilker, A. Newberg, and M. Battistini Pilot Study on the Effect of Estrogen Replacement Therapy on Brain Dopamine Transporter Availability in Healthy, Postmenopausal Women Am J Geriatr Psychiatry, December 1, 2004; 12(6): 621 - 630. [Abstract] [Full Text] [PDF]